Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Bridging ASCVD Care Between Academic and Rural Settings
Statins and Safety: What the Data Say About Dementia, Cancer, and More
From Risk to Results: Cases in ASCVD Prevention and Treatment
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
When and Why to Use CAC Scoring
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink
Jennifer B. Green, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.